Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Colorectal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm
Colorectal Neoplasm

Subtype

Colorectal Neoplasm

CI-CAN-00002404Explore in graph →

Non-malignant1,783 active trials21 approved drugs382 evidence items

NCIt: C2956
MeSH: D015179

Overview
Statistics
Survival
Genomics27
Variants & evidence382
Drugs79
Trials8601
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
· Cell Rep · 2014 · PMID 24685132 · validated civic_curation pubmed
HER2 activating mutations are targets for colorectal cancer treatment.
· Cancer Discov · 2015 · PMID 26243863 · validated civic_curation pubmed
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
· Oncotarget · 2016 · PMID 27167191 · validated civic_curation pubmed
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
· Cancer Biol Ther · 2014 · PMID 24642870 · validated civic_curation pubmed
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
· Cancer Res · 2010 · PMID 20570890 · validated civic_curation pubmed
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
· Cancer Cell · 2013 · PMID 23845441 · validated civic_curation pubmed

Showing 301–325 of 357 publications

← Previous
1
…
12
13
14
15
Next →

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

· Cancer Res · 2012 · PMID 22180495 · validated civic_curation pubmed

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

· J Clin Oncol · 2008 · PMID 18202412 · validated civic_curation pubmed

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

· Cancer Res · 2012 · PMID 22440753 · validated civic_curation pubmed

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

· Int J Cancer · 2015 · PMID 25242168 · validated civic_curation pubmed

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

· Cell Death Dis · 2014 · PMID 25210794 · validated civic_curation pubmed

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.

· J Clin Invest · 2013 · PMID 23867504 · validated civic_curation pubmed

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

· Oncogene · 2011 · PMID 20956938 · validated civic_curation pubmed

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

· J Clin Invest · 2011 · PMID 21985784 · validated civic_curation pubmed

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

· Nature · 2012 · PMID 22281684 · validated civic_curation pubmed

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

· Clin Cancer Res · 2013 · PMID 23549875 · validated civic_curation pubmed

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

· Clin Cancer Res · 2012 · PMID 22392911 · validated civic_curation pubmed

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

· Mol Cancer Ther · 2016 · PMID 27364904 · validated civic_curation pubmed

Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.

· Sci Rep · 2016 · PMID 27197561 · validated civic_curation pubmed

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

· Nature · 2017 · PMID 28783719 · validated civic_curation pubmed

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

· Clin Cancer Res · 2015 · PMID 26296355 · validated civic_curation pubmed

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

· Cancer Res · 2017 · PMID 28512242 · validated civic_curation pubmed

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.

· Anticancer Drugs · 2014 · PMID 25089570 · validated civic_curation pubmed

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

· Digestion · 2013 · PMID 24135816 · validated civic_curation pubmed